GlassScriptPhysician profile
Mayurathan Kesavan
NPI 1851687958
$167,412.71
in general payments reported to CMS, 2019-2025
37 companies · $54K in 2025
The $54K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $572 · 2021: $10K · 2022: $10K · 2023: $28K · 2024: $64K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $142K · Food and Beverage: $3,457 · Education: $45.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $142,436.67 |
| Food and Beverage | $3,456.54 |
| Education | $45.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $162,476.67 | 2021-2025 | Capsocam Colon, Capsocam Plus |
| Abbvie INC. | $928.54 | 2019-2025 | |
| Capsopro Services LLC | $500.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $446.99 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $329.20 | 2021-2025 | Tremfya, Stelara, Remicade |
| Ardelyx, INC. | $263.86 | 2023-2024 | Ibsrela |
| Celgene Corporation | $247.64 | 2021-2024 | Zeposia |
| Pfizer INC. | $240.25 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.63 | 2022-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $159.09 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $157.29 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $128.77 | 2022 | |
| Thd America, INC. | $124.23 | 2022 | |
| Ironwood Pharmaceuticals, INC | $115.86 | 2022-2025 | Linzess |
| Ipsen Biopharmaceuticals, INC | $108.03 | 2024-2025 | Iqirvo, Bylvay |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $104.40 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $99.39 | 2022-2024 | Injectafer |
| Boston Scientific Corporation | $95.42 | 2022 | |
| Merck Sharp & Dohme LLC | $90.94 | 2023-2024 | Dificid, Zinplava |
| Braintree Laboratories, INC. | $79.20 | 2019-2024 | Suflave, Sutab |
| Celltrion USA INC. | $59.57 | 2024 | Vegzelma, Zymfentra |
| Organon LLC | $59.42 | 2023 | Hadlima |
| Intercept Pharmaceuticals, INC. | $58.29 | 2022-2024 | Ocaliva |
| Qol Medical, LLC | $49.53 | 2022-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $46.88 | 2022-2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.66 | 2023-2024 | Cyltezo |
| Madrigal Pharmaceuticals | $32.74 | 2025 | Rezdiffra |
| Ucb, INC. | $29.35 | 2019-2020 | |
| Medtronic, INC. | $28.61 | 2024 | Interstim |
| Fresenius Kabi USA, LLC | $21.13 | 2023 | Idacio |
| Phathom Pharmaceuticals, INC. | $18.92 | 2024 | Voquezna |
| Gilead Sciences, INC. | $18.31 | 2024 | |
| Alnylam Pharmaceuticals INC. | $18.27 | 2024 | Givlaari |
| Digestive Care, INC. | $16.85 | 2024 | Pertzye |
| Sandoz INC. | $14.86 | 2024 | Hyrimoz |
| Intra-Sana Laboratories | $14.32 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Aimmune Therapeutics, INC. | $13.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayurathan Kesavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.